Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific T-H1 and T-H2 cell responses in Cry j 2-primed mice
Autore:
Hirahara, K; Saito, S; Serizawa, N; Sasaki, R; Sakaguchi, M; Inouye, S; Taniguchi, Y; Kaminogawa, S; Shiraishi, A;
Indirizzi:
Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan Sankyo CoLtd Tokyo Japan 1408710 bs, Shinagawa Ku, Tokyo 1408710, Japan Jikei Univ, Sch Med, Tokyo, Japan Jikei Univ Tokyo JapanJikei Univ, Sch Med, Tokyo, Japan Natl Inst Infect Dis, Tokyo, Japan Natl Inst Infect Dis Tokyo JapanNatl Inst Infect Dis, Tokyo, Japan Hayashibara Biochem Labs Inc, Okayama, Japan Hayashibara Biochem Labs IncOkayama Japan hem Labs Inc, Okayama, Japan Univ Tokyo, Tokyo, Japan Univ Tokyo Tokyo JapanUniv Tokyo, Tokyo, Japan
Titolo Testata:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
fascicolo: 6, volume: 102, anno: 1998,
parte:, 1
pagine: 961 - 967
SICI:
0091-6749(199812)102:6<961:OAOADT>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
JAPANESE CEDAR POLLEN; 2ND MAJOR ALLERGEN; SUGI BASIC-PROTEIN; J-I; MONOCLONAL-ANTIBODIES; AUTOIMMUNE-DISEASES; ANTIGENIC ANALYSES; CHOLERA-TOXIN; TOLERANCE; INDUCTION;
Keywords:
Japanese cedar pollen; pollinosis; oral immunotherapy; oral tolerance; peptide; T cell epitope; T-H1/T-H2; IgE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Shiraishi, A Sankyo408710,, Biol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1 Sankyo Co Ltd 2-58 Hiromachi 1 Chome Tokyo Japan 1408710 o 1
Citazione:
K. Hirahara et al., "Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific T-H1 and T-H2 cell responses in Cry j 2-primed mice", J ALLERG CL, 102(6), 1998, pp. 961-967

Abstract

Background: Oral immunotherapy with a peptide for allergic immune responses is theoretically a promising therapy but has not been established yet. Objective: To evaluate immune suppressive efficacy of oral administration of an immunodominant peptide, we investigated changes in T-cell proliferation, T-H1- and T-H2-cytokine production, and T-H1- and T-H2-mediated antibody production in mice after oral administration of a peptide. Methods: Peptide p246-259, containing a dominant T-cell determinant of Cryj 2, which is the major allergen in Japanese cedar pollen, was used in this study. Groups of mice received p246-259 or PBS alone before or after theywere primed intranasally with Cry j 2 and cholera toxin. In another experiment mice were primed intraperitoneally with Cry j 2 and alum, Proliferative response and cytokine production by nasal-associated lymph node cells against Cry j 2 were investigated. Amounts of systemic anti-Cry j 2 IgE and IgG antibodies were also measured. Results: Oral administration of the peptide to mice before, or even after,the sensitization induced oral tolerance in T-cell responses against the allergen; the tolerance was associated with decreased production of T-H1 (IFN-gamma and IL-2) and T-H2 (IL-4) cytokines. Allergen-specific T-H1-mediated (IgG2a and IgG2b) and T-H2-mediated (IgG1 and IgE) antibody responses were also inhibited. Conclusions: Oral administration of a dominant T-cell determinant peptide induces immunologic tolerance in both T-H1 and T-H2 cell responses against the whole protein allergen. Our study is the first, to our knowledge, to demonstrate the potential for peptide-based oral immunotherapy in order to treat allergic immune responses.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 02:04:37